​

Oncolytics Biotech Stock (NASDAQ:ONCY)

ForecastOwnershipFinancialsChart
Oncolytics Biotech by TradingView

Previous Close

$0.79

52W Range

$0.74 - $1.51

50D Avg

$0.87

200D Avg

$0.97

Market Cap

$75.43M

Avg Vol (3M)

$1.40M

Beta

1.09

Div Yield

-

ONCY Company Profile

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

29

IPO Date

Oct 05, 2001

Website

ONCY Performance

ONCY Financial Summary

Dec 23Dec 22Dec 21
Revenue---
Operating Income$-33.79M$-28.57M$-26.23M
Net Income$-27.75M$-24.84M$-26.30M
EBITDA$-33.39M$-28.18M$-25.66M
Basic EPS$-0.41$-0.62$-0.49
Diluted EPS$-0.41$-0.62$-0.49

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts

Q1 25May 14, 25 | 4:30 PM
Q4 24Mar 07, 25 | 8:30 AM
Q3 24Nov 12, 24 | 8:30 AM

Peer Comparison

TickerCompany
WHWKWhitehawk Therapeutics Inc
CLNNClene Inc.
ZNTLZentalis Pharmaceuticals, Inc.
SRZNSurrozen, Inc.
TVGNTevogen Bio Holdings Inc.
TILInstil Bio, Inc.
IMMXImmix Biopharma, Inc.
COYACoya Therapeutics, Inc.
MGNXMacroGenics, Inc.
ATOSAtossa Therapeutics, Inc.